Levels of uPA and PAI-1 in breast cancer and its correlation to Ki67-index and results of a 21-multigene-array

Diagnostic Pathology
Hans-Ullrich VölkerLea Frey

Abstract

Conventional parameters including Ki67, hormone receptor and Her2/neu status are used for risk stratification for breast cancer. The serine protease urokinase plasminogen activator (uPA) and the plasminogen activator inhibitor type-1 (PAI-1) play an important role in tumour invasion and metastasis. Increased concentrations in tumour tissue are associated with more aggressive potential of the disease. Multigene tests provide detailed insights into tumour biology by simultaneously testing several prognostically relevant genes. With OncotypeDX®, a panel of 21 genes is tested by means of quantitative real-time polymerase chain reaction. The purpose of this pilot study was to analyse whether a combination of Ki67 and uPA/PAI-1 supplies indications of the result of the multigene test. The results of Ki67, uPA/PAI-1 and OncotypeDX® were analysed in 25 breast carcinomas (luminal type, pT1/2, max pN1a, G2). A statistical and descriptive analysis was performed. With a proliferation index Ki67 of < 14%, the recurrence score (RS) from the multigene test was on average in the low risk range, with an intermediate RS usually resulting if Ki67 was > 14%. Not elevated values of uPA and PAI-1 showed a lower rate of proliferation (average 8.5%) t...Continue Reading

References

Aug 19, 2000·Cellular and Molecular Life Sciences : CMLS·P A AndreasenH H Petersen
Sep 9, 2000·Current Opinion in Cell Biology·K T PreissnerA E May
Apr 20, 2004·Journal of Cellular Biochemistry·Yabing ChenDavid J Schneider
May 25, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Soonmyung PaikNorman Wolmark
May 23, 2008·Immunology Letters·Bernd R Binder, Judit Mihaly
Aug 6, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lori J GoldsteinJoseph A Sparano
Feb 10, 2009·Current Cancer Drug Targets·Salvatore UlisseMassimino D'Armiento
Jan 13, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eleftherios P MamounasNorman Wolmark
Mar 16, 2013·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·N HarbeckUNKNOWN Chemo-N 0 Study Group
Aug 27, 2013·Breast Cancer Research and Treatment·Josh J Carlson, Joshua A Roth
May 23, 2015·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Marko ButaDragica Nikolić-Vukosavljević
Sep 26, 2015·Cancer Biomarkers : Section a of Disease Markers·Zaki Abu RabiDragica Nikolić-Vukosavljević
Feb 10, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lyndsay N HarrisUNKNOWN American Society of Clinical Oncology
Sep 29, 2017·BMC Cancer·Elise DelucheNicole Tubiana-Mathieu

❮ Previous
Next ❯

Citations

Jan 6, 2021·Molecular and Cellular Biochemistry·Ma Eugenia Garay-SevillaArmando Rojas
Apr 21, 2021·Expert Review of Molecular Diagnostics·Rajesh AhirwarSaroj Kumar
Dec 4, 2020··Ammar Rasoul Mohammed RudhaZahraa Mohammed AL-Nafakh

❮ Previous
Next ❯

Methods Mentioned

BETA
ELISA
protein assay

Related Concepts

Related Feeds

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.